Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data.
Anna Buda-NowakŁukasz KwintaPaweł PotockiAnna Michałowska-KaczmarczykAgnieszka SłowikKamil KonopkaJoanna StrebMaciej KoniewskiPiotr J WysockiPublished in: Journal of clinical medicine (2023)
Metronomic chemo-endocrine therapy with FulVEC regimen represents an interesting option and compares favorably with other approaches in patients' refractory to endocrine treatments. A phase II randomized trial is warranted.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- clinical trial
- stem cells
- photodynamic therapy
- peritoneal dialysis
- combination therapy
- squamous cell carcinoma
- mesenchymal stem cells
- radiation therapy
- patient reported outcomes
- deep learning
- cell therapy
- locally advanced
- breast cancer cells